Taikang Asset Management (Hong Kong) CO LTD Vir Biotechnology, Inc. Transaction History

Taikang Asset Management (Hong Kong) CO LTD

$937 Million
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$19.08 - $26.7 $10.2 Million - $14.2 Million	-533,332 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$26.34 - $83.07 $2.34 Million - $7.38 Million	-88,889 Reduced 14.29%	533,332 $27.3 Million
Q2 2020 Aug 12, 2020	BUY	$27.89 - $47.86 $17.4 Million - $29.8 Million	622,221 New	622,221 $25.5 Million

Others Institutions Holding VIR

# of Institutions

219

Shares Held

87.4M

Call Options Held

127K

Put Options Held

1.19M

Sb Investment Advisers (Uk) LTD London, X0

16.7M
Shares

$116 Million
1.03% of portfolio
Black Rock Inc. New York, NY

16.4M
Shares

$114 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

13.1M
Shares

$91.3 Million
0.0% of portfolio
State Street Corp Boston, MA

5.63M
Shares

$39.1 Million
0.0% of portfolio
Orbimed Advisors LLC San Diego, CA

3.57M
Shares

$24.8 Million
0.63% of portfolio

View Full List

About Vir Biotechnology, Inc.

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $922M
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

More about VIR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Taikang Asset Management (Hong Kong) CO LTD, based on Form 13F filings with the SEC.

News

Stay updated on Taikang Asset Management (Hong Kong) CO LTD with notifications on news.

Account